SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Hyaluronic acid	GHK-Cu	SNAP-8 (Acetyl Octapeptide-3)
Research Topic	Tissue / Repair Research	Tissue / Repair Research	Tissue / Repair Research
Pharmacology	Glycosaminoglycan / formulation-specific biomaterial	Copper(II)-binding tripeptide complex / tissue-remodelling research	Synthetic cosmetic octapeptide; proposed SNARE-related activity, not botulinum toxin
PrimeCore Class	Class ENeeds Verification	Class CExperimental / limited evidence	Class CExperimental / limited evidence
Evidence Grade	Grade BStrong controlled human evidence	Grade CEarly human evidence	Grade DLimited / observational evidence
Evidence boundary	Hyaluronic acid is a glycosaminoglycan, not a peptide. Cosmetic ingredients, approved dermal fillers and joint products are not interchangeable. FDA approval concerns specific devices and indications, not an unspecified HA vial. Intravascular filler complications can include tissue necrosis, blindness and stroke.	A copper-binding tripeptide with route-specific evidence; topical cosmetic research does not establish injectable systemic benefit.	SNAP-8 is associated with the cosmetic ingredient acetyl octapeptide-3, not Argireline or botulinum toxin. Limited human studies concern multi-ingredient serum and hyaluronic-acid microneedle patches, not isolated SNAP-8. The serum study enrolled 33 women and analysed 31 completers without a concurrent human control; its authors were company employees. Formulation outcomes cannot establish peptide-only efficacy, Botox equivalence or injection safety. Cosmetic notification and INCI/CosIng information do not establish injectable drug approval; exact product status remains unverified.
Unknowns	Insufficient data in the current dataset	clinical benefit and long-term safety of injectable GHK-Cu whether results from an older topical ulcer gel replicate in modern confirmatory trials optimal and safe formulation for each topical indication without extrapolating dose or route clinical relevance of collagen, gene-expression and matrix biomarkers results of Phase 2 NCT07437586, which has no posted results outcome of the planned FDA PCAC review before the end of February 2027; date and location remained unscheduled on 23 August 2026	Insufficient data in the current dataset
Limitations	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) Skin-care HA ≠ authorised dermal filler ≠ joint product; Grade B อ้างบริบทผลิตภัณฑ์ที่ประเมิน ไม่ใช่คะแนนของสารจากผู้ขาย	The human literature is small, old or formulation-specific. One controlled ulcer study has a positive abstract but does not report the total sample size there; the post-laser study had only 13 completers and no significant objective benefit. Cosmetic studies often use multiple ingredients and surrogate appearance endpoints. Preclinical mechanisms do not establish clinical outcomes, and topical evidence cannot be transferred to injection or systemic use.	Insufficient data in the current dataset
Sources	FDA · dermal-filler risks and restrictions FDA · approved dermal fillers	https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs https://clinicaltrials.gov/study/NCT07437586 https://pubmed.ncbi.nlm.nih.gov/17147644/ https://pubmed.ncbi.nlm.nih.gov/16847171/ https://pubmed.ncbi.nlm.nih.gov/11121126/ https://pubmed.ncbi.nlm.nih.gov/11045606/ https://single-market-economy.ec.europa.eu/sectors/cosmetics/cosmetic-ingredient-database/cosing-glossary-ingredients_en https://products.mhra.gov.uk/	https://pubmed.ncbi.nlm.nih.gov/35426243/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10084013/ https://pubmed.ncbi.nlm.nih.gov/31134751/ https://pubmed.ncbi.nlm.nih.gov/18498523/ https://www.lubrizol.com/solutions/products/beauty/detail-pages/snap-8-peptide-solution-c https://www.fda.moph.go.th/news/%E0%B8%A2%E0%B8%B2%E0%B8%89%E0%B8%B5%E0%B8%94 https://www.fda.gov/cosmetics/cosmetic-products/wrinkle-treatments-and-other-anti-aging-products https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devices https://single-market-economy.ec.europa.eu/sectors/cosmetics/cosmetic-ingredient-database_en
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.